Relationship Between the Serum Total Bilirubin and Inflammation in Patients With Psoriasis Vulgaris

Journal of Clinical Laboratory Analysis

Volumn 30, Issue 5, 2016, Pages 768-775

  Zhou, Zhen Xing ^a   Chen, Jian Kui ^b   Hong, Yan Ying ^a   Zhou, Ru ^c   Zhou, Dong Mei ^a   Sun, Li Yun ^a   Qin, Wen Li ^d   Wang, Tian Cheng ^e  

^a BEIJING HOSPITAL OF TRADITIONAL CHINESE MEDICINE AFFILIATED TO CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

bilirubin, inflammation; CRP; logistic regression; psoriasis vulgaris

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATINE KINASE; CREATININE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFLAMMATION; LEUKOCYTE COUNT; LEUKOCYTE DIFFERENTIAL COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS;

EID: 84989245411     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21936     Document Type: Article

References (43)

1. Bhole VM, Choi HK, Burns LC, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford) 2012;51:552–556.
2. Coimbra S, Oliveira H, Reis F, et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol 2010;24:789–796.
3. Devaraj S, Kumaresan PR, Jialal I. C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: Further evidence of endothelial dysfunction. Clin Chem 2011;57:1757–1761.
4. Di Napoli M, Papa F. Association between blood pressure and C-reactive protein levels in acute ischemic stroke. Hypertension 2003;42:1117–1123.
5. Wang J, Song J, Wu J, He C, Xu C, Liu Y. Leukocyte and leukocyte subset counts reveal compensatory mechanisms in coronary heart disease. Clin Chim Acta 2013;418:79–85.
6. Enerbäck C. Soluble biomarkers in psoriasis. Eur J Dermatol 2011;21:844–850.
7. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004;150:917–928.
8. Khansari N, Shakiba Y, Mahmoudi M. Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Pat Inflamm Allergy Drug Discov 2009;3:73–80.
9. Bhattacharyya A, Chattopadhyay R, Mitra S, Crowe SE. Oxidative stress: An essential factor in the pathogenesis of gastrointestinal mucosal diseases. Physiol Rev 2014;94:329–354.
10. Lugrin J, Rosenblatt-Velin N, Parapanov R, Liaudet L. The role of oxidative stress during inflammatory processes. Biol Chem 2014;395:203–230.
11. Chen YH, Chau LY, Chen JW, Lin SJ. Serum bilirubin and ferritin levels link heme oxygenase-1 gene promoter polymorphism and susceptibility to coronary artery disease in diabetic patients. Diabetes Care 2008;31:1615–1620.
12. Paine A, Eiz-Vesper B, Blasczyk R, Immenschuh S. Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential. Biochem Pharmacol 2010;80:1895–1903.
13. Zhang ZY, Bian LQ, Kim SJ, Zhou CC, Choi YH. Inverse relation of total serum bilirubin to coronary artery calcification score detected by multidetector computed tomography in males. Clin Cardiol 2012;35:301–306.
14. Vítek L. The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front Pharmacol 2012;3:55.
15. Wegiel B, Otterbein LE. Go green: The anti-inflammatory effects of biliverdin reductase. Front Pharmacol 2012;3:47.
16. Gul M, Uyarel H, Ergelen M, et al. Prognostic value of total bilirubin in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention. Am J Cardiol 2013;111:166–171.
17. Mayer M. Association of serum bilirubin concentration with risk of coronary artery disease. Clin Chem 2000;46:1723–1727.
18. Ohnaka K, Kono S, Inoguchi T, et al. Inverse associations of serum bilirubin with high sensitivity C-reactive protein, glycated hemoglobin, and prevalence of type 2 diabetes in middle-aged and elderly Japanese men and women. Diabetes Res Clin Pract 2010;88:103–110.
19. Yu K, Kim C, Sung E, Shin H, Lee H. Association of serum total bilirubin with serum high sensitivity C-reactive protein in middle-aged men. Korean J Fam Med 2011;32:327–333.
20. Zhou Q, Mrowietz U, Rostami-Yazdi M. Oxidative stress in the pathogenesis of psoriasis. Free Radic Biol Med 2009;47:891–905.
21. Oh SW, Lee ES, Kim S, et al. Bilirubin attenuates the renal tubular injury by inhibition of oxidative stress and apoptosis. BMC Nephrol 2013;14:105.
22. Severin E, Nave B, Ständer M, Ott R, Traupe H. Total antioxidative capacity is normal in sera from psoriasis patients despite elevated bilirubin, tocopherol and urate levels. Dermatology 1999;198:336–339.
23. Balta S, Balta I, Mikhailidis DP, et al. Bilirubin levels and their association with carotid intima media thickness and high-sensitivity C-reactive protein in patients with psoriasis vulgaris. Am J Clin Dermatol 2014;15:137–142.
24. Nemati H, Khodarahmi R, Sadeghi M, Ebrahimi A, Rezaei M, Vaisi-Raygni A. Antioxidant status in patients with psoriasis. Cell Biochem Funct 2014;32:268–273.
25. Coimbra S, Oliveira H, Reis F, et al. Erythroid disturbances before and after treatment of Portuguese psoriasis vulgaris patients: A cross-sectional and longitudinal study. Am J Clin Dermatol 2012;13:37–47.
26. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002;25:2016–2021.
27. Khan HA, Alhomida AS, Sobki SH, Moghairi AA, Koronki HE. Blood cell counts and their correlation with creatine kinase and C-reactive protein in patients with acute myocardial infarction. Int J Clin Exp Med 2012;5:50–55.
28. Yamada S, Gotoh T, Nakashima Y, et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. Am J Epidemiol 2001;153:1183–1190.
29. Yang JY, Nam JS, Choi HJ. Association between high-sensitivity C-reactive protein with arterial stiffness in healthy Korean adults. Clin Chim Acta 2012;413:1419–1423.
30. Schön MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352:1899–1912.
31. Schön MP, Boehncke WH, Bröcker EB. Psoriasis: Clinical manifestations, pathogenesis and therapeutic perspectives. Discov Med 2005;5:253–258.
32. Suárez-Fariñas M, Li K, Fuentes-Duculan J, Hayden K, Brodmerkel C, Krueger JG. Expanding the psoriasis disease profile: Interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol 2012;132:2552–2564.
33. Tam LS, Tomlinson B, Chu TT, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls–the role of inflammation. Rheumatology (Oxford) 2008;47:718–723.
34. Strober BE, Poulin Y, Teller C, Wang Y, Williams DA, Goldblum OM. Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy. J Eur Acad Dermatol Venereol 2014;28:1701–1706.
35. Beygi S, Lajevardi V, Abedini R. C-reactive protein in psoriasis: A review of the literature. J Eur Acad Dermatol Venereol 2014;28:700–711.
36. Xu T, Zhang YH. Association of psoriasis with stroke and myocardial infarction: Meta-analysis of cohort studies. Br J Dermatol 2012;167:1345–1350.
37. Maradit-Kremers H, Icen M, Ernste FC, Dierkhising RA, McEvoy MT. Disease severity and therapy as predictors of cardiovascular risk in psoriasis: A population-based cohort study. J Eur Acad Dermatol Venereol 2012;26:336–343.
38. Balta I, Balta S, Demirkol S, et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: Correlations with cardiovascular risk and activity of disease. Br J Dermatol 2013;169:1066–1070.
39. Balta I, Balta S, Demirkol S, et al. Aortic arterial stiffness is a moderate predictor of cardiovascular disease in patients with psoriasis vulgaris. Angiology 2014;65:74–78.
40. Choi SH, Yun KE, Choi HJ. Relationships between serum total bilirubin levels and metabolic syndrome in Korean adults. Nutr Metab Cardiovasc Dis 2013;23:31–37.
41. Dullaart RP, Kappelle PJ, de Vries R. Lower carotid intima media thickness is predicted by higher serum bilirubin in both non-diabetic and Type 2 diabetic subjects. Clin Chim Acta 2012;414:161–165.
42. Navarini AA, Poulin Y, Menter A, Gu Y, Teixeira HD. Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis. J Drugs Dermatol 2014;13:554–562.
43. Chularojanamontri L, Griffiths CE, Chalmers RJ. The Simplified Psoriasis Index (SPI): A practical tool for assessing psoriasis. J Invest Dermatol 2013;133:1956–1962.